ASH 2020 | MMR antibody titers in post-ASCT myeloma patients
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, outlines the results of a study analyzing the levels of IgG antibodies against measles, mumps, and rubella (MMR) in multiple myeloma patients following autologous stem cell transplant (ASCT). Data shows that post-ASCT, patients treated with traditional compounds have reduced antibody titers to vaccine-preventable diseases, necessitating re-vaccination. Plasma samples were collected from patients approximately 100 days after transplant and their antibody titers were compared to those of healthy, vaccinated controls. Serial samples from 45 myeloma patients were also tested to compare results before and after ASCT. The study did not find significant reductions in relative MMR antibody levels, suggesting re-vaccination may no longer be required following the introduction of novel induction treatment compounds. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Rafael Fonseca, MD, has done consultancy work with Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Karyopharm, Merck, Juno, Kite, Aduro, OncoTracker, Oncopeptides, GSK and AbbVie; and has participated in scientific advisory boards for Adaptive Biotechnologies, Caris Life Sciences and OncoTracker.
